1 October 2009 Business
Industry news, October 2009
After months of wrangling, GlaxoSmithKline (GSK) has found enough common ground with Human Genome Sciences (HGS) for the two to sign up to a $3.6 billion (£2.3 billion) takeover deal.
The two companies have worked together for over 20 years on several products, including the development of benlimumab, marketed as Benlysta, the first new treatment for lupus erythematosus in half a century. Benlimumab, a monoclonal antibody, was approved by US authorities in March 2011, and analysts are predicting peak sales of $3–7 million per year.
GSK says the deal will lead to cost savings across the combined business of $200 million.
22 May 2013 News and Analysis
An Indiana farmer who was trying to replicate Monsanto-patented seeds infringed on the company’s intellectual property righ...
24 May 2013 Research
New technique can tell left from right even at low concentrations